Why should every adult get a 3rd shot (booster) when eligible (6 months after 1°💉)? 1. A randomized, placebo-controlled trial, the gold standard for assessing efficacy, showed restoration of efficacy to 95.6%, in >10,000 participants across all age groups
2. Prevention of hospitalizations and deaths in a study of >728,000 people w/ 3-shots vs >728,000 matched controls (2-shots) thelancet.com/journals/lance…@TheLancet
3. We have no US National data by vaxx status but hospitalizations are starting to increase again and several states are reporting an increasing proportion of breakthroughs accounting for them
4. The US is doing a poor job of rolling out boosters relative to many other countries.
Only 1 in 3 people of the highest risk group, age 65+, have received one. Only 1 in 7 overall who are eligible.
5. Despite the compelling data and the current predicament, there is unwarranted and serious division at the top @CDCgov and among some experts who have been in denial of the vaccine effectiveness waning issue for months, resulting in mixed messages to the public and confusion
6. Meanwhile, 2 states have taken the appropriate steps of opening up boosters for all over the age 18 (California and Colorado) which is unprecedented (overriding CDC and FDA). And many countries have made boosters eligible for all adults their policy, including Canada.
7. Getting a booster when there'a a surge in your state is not the best timing ;-)
Also highlights that the booster rate across the US is remarkably low.
8. New data today from the UK shows boosters restore vaccine effectiveness for protection vs symptomatic infection to over 90% (AZ 93%, Pfizer 94%) khub.net/documents/1359… gov.uk/government/new…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.
My oped on the JN.1 variant and the 2nd biggest US wave of infections (after Omicron) since the pandemic began
@latimes @latimesopinion #LongCovid latimes.com/opinion/story/…
Recent @CDCgov #SARSCoV2 wastewater data for current wave (vs Omicron Jan 2022 and subsequent waves), graph by @luckytran
Sorry, @washingtonpost, but this is not "another Covid-19 uptick" as you put it in your Health Alert. You ignore the best metric for infections that we have at present—wastewater—focusing only on hospitalizations washingtonpost.com/health/2024/01…